IRIS Accounts Production v24.3.2.46 SC502582 Board of Directors 1.6.23 31.5.24 31.5.24 0 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhSC5025822023-05-31SC5025822024-05-31SC5025822023-06-012024-05-31SC5025822022-05-31SC5025822022-06-012023-05-31SC5025822023-05-31SC502582ns15:Scotland2023-06-012024-05-31SC502582ns14:PoundSterling2023-06-012024-05-31SC502582ns10:Director12023-06-012024-05-31SC502582ns10:PrivateLimitedCompanyLtd2023-06-012024-05-31SC502582ns10:SmallEntities2023-06-012024-05-31SC502582ns10:AuditExempt-NoAccountantsReport2023-06-012024-05-31SC502582ns10:SmallCompaniesRegimeForDirectorsReport2023-06-012024-05-31SC502582ns10:SmallCompaniesRegimeForAccounts2023-06-012024-05-31SC502582ns10:FullAccounts2023-06-012024-05-31SC50258212023-06-012024-05-31SC502582ns10:Director22023-06-012024-05-31SC502582ns10:CompanySecretary12023-06-012024-05-31SC502582ns10:RegisteredOffice2023-06-012024-05-31SC502582ns5:CurrentFinancialInstruments2024-05-31SC502582ns5:CurrentFinancialInstruments2023-05-31SC502582ns5:ShareCapital2024-05-31SC502582ns5:ShareCapital2023-05-31SC502582ns5:RetainedEarningsAccumulatedLosses2024-05-31SC502582ns5:RetainedEarningsAccumulatedLosses2023-05-31SC50258212023-06-012024-05-31SC502582ns5:NetGoodwill2023-06-012024-05-31SC502582ns5:LandBuildingsns5:OwnedOrFreeholdAssets2023-06-012024-05-31SC502582ns5:PlantMachinery2023-06-012024-05-31SC502582ns5:FurnitureFittings2023-06-012024-05-31SC502582ns5:ComputerEquipment2023-06-012024-05-31SC502582ns5:NetGoodwill2023-05-31SC502582ns5:NetGoodwill2024-05-31SC502582ns5:NetGoodwill2023-05-31SC502582ns5:LandBuildings2023-05-31SC502582ns5:PlantMachinery2023-05-31SC502582ns5:FurnitureFittings2023-05-31SC502582ns5:ComputerEquipment2023-05-31SC502582ns5:LandBuildings2023-06-012024-05-31SC502582ns5:LandBuildings2024-05-31SC502582ns5:PlantMachinery2024-05-31SC502582ns5:FurnitureFittings2024-05-31SC502582ns5:ComputerEquipment2024-05-31SC502582ns5:LandBuildings2023-05-31SC502582ns5:PlantMachinery2023-05-31SC502582ns5:FurnitureFittings2023-05-31SC502582ns5:ComputerEquipment2023-05-31SC502582ns5:WithinOneYearns5:CurrentFinancialInstruments2024-05-31SC502582ns5:WithinOneYearns5:CurrentFinancialInstruments2023-05-31
REGISTERED NUMBER: SC502582 (Scotland)















UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MAY 2024

FOR

STEPHEN MCCORMICK PHARMACIES LIMITED

STEPHEN MCCORMICK PHARMACIES LIMITED (REGISTERED NUMBER: SC502582)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


STEPHEN MCCORMICK PHARMACIES LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MAY 2024







DIRECTORS: S McCormick
Mrs I McCormick





SECRETARY: Mrs I McCormick





REGISTERED OFFICE: 64 Mill Of Shield Road
Drongan
Ayr
Ayrshire
KA6 7AY





REGISTERED NUMBER: SC502582 (Scotland)





ACCOUNTANTS: Galbraith Pritchards
20 Barns Street
Ayr
Ayrshire
KA7 1XA

STEPHEN MCCORMICK PHARMACIES LIMITED (REGISTERED NUMBER: SC502582)

BALANCE SHEET
31 MAY 2024

31/5/24 31/5/23
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 135,000 270,000
Tangible assets 5 167,582 179,140
302,582 449,140

CURRENT ASSETS
Stocks 60,603 61,721
Debtors 6 243,037 218,618
Cash at bank and in hand 213,146 247,895
516,786 528,234
CREDITORS
Amounts falling due within one year 7 265,798 265,768
NET CURRENT ASSETS 250,988 262,466
TOTAL ASSETS LESS CURRENT
LIABILITIES

553,570

711,606

PROVISIONS FOR LIABILITIES 18,947 20,896
NET ASSETS 534,623 690,710

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 534,523 690,610
SHAREHOLDERS' FUNDS 534,623 690,710

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 May 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 May 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

STEPHEN MCCORMICK PHARMACIES LIMITED (REGISTERED NUMBER: SC502582)

BALANCE SHEET - continued
31 MAY 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 18 February 2025 and were signed on its behalf by:





S McCormick - Director


STEPHEN MCCORMICK PHARMACIES LIMITED (REGISTERED NUMBER: SC502582)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024


1. STATUTORY INFORMATION

Stephen Mccormick Pharmacies Limited is a private company, limited by shares , registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Critical accounting judgements and key sources of estimation uncertainty
In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2015, is being amortised evenly over its estimated useful life of ten years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Freehold property - not provided
Plant and machinery - 20% on reducing balance and 5% on cost
Fixtures and fittings - 15% on reducing balance
Computer equipment - 33.33% on cost

Depreciation is not provided on freehold property as it is maintained to such a standard that its value is not impaired by the passage of time.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments
The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.


STEPHEN MCCORMICK PHARMACIES LIMITED (REGISTERED NUMBER: SC502582)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2024


2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - 15 ).

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 June 2023
and 31 May 2024 1,350,000
AMORTISATION
At 1 June 2023 1,080,000
Charge for year 135,000
At 31 May 2024 1,215,000
NET BOOK VALUE
At 31 May 2024 135,000
At 31 May 2023 270,000

STEPHEN MCCORMICK PHARMACIES LIMITED (REGISTERED NUMBER: SC502582)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2024


5. TANGIBLE FIXED ASSETS
Fixtures
Freehold Plant and and Computer
property machinery fittings equipment Totals
£    £    £    £    £   
COST
At 1 June 2023 74,663 111,956 85,388 19,965 291,972
Additions - - 855 - 855
At 31 May 2024 74,663 111,956 86,243 19,965 292,827
DEPRECIATION
At 1 June 2023 - 40,276 58,682 13,874 112,832
Charge for year - 5,821 4,054 2,538 12,413
At 31 May 2024 - 46,097 62,736 16,412 125,245
NET BOOK VALUE
At 31 May 2024 74,663 65,859 23,507 3,553 167,582
At 31 May 2023 74,663 71,680 26,706 6,091 179,140

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31/5/24 31/5/23
£    £   
Trade debtors 193,896 173,792
VAT 47,252 43,013
Prepayments 1,889 1,813
243,037 218,618

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31/5/24 31/5/23
£    £   
Trade creditors 178,487 173,494
Tax 39,158 24,567
Social security and other taxes 200 -
Directors' current accounts 2,644 23,412
Deferred income 40,841 40,164
Accrued expenses 4,468 4,131
265,798 265,768

8. RELATED PARTY DISCLOSURES

During the year £6,000 (2023 £6,000) was paid to the directors for rent of a shop owned by them.

Included in creditors at the year end were directors loans of £2,644 (2023 £23,412). No interest is charged on these loans and there is no fixed date for repayment.

STEPHEN MCCORMICK PHARMACIES LIMITED (REGISTERED NUMBER: SC502582)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2024


9. ULTIMATE CONTROLLING PARTY

The directors consider that there is no ultimate controlling party as the directors, Mr and Mrs McCormick, each
own 50% of the issued share capital of the company